Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial

Radiotherapy and Oncology

Volumn 96, Issue 1, 2010, Pages 13-18

  Al Mamgani, Abrahim ^a   Heemsbergen, Wilma D ^b   Levendag, Peter C ^a   Lebesque, Joos V ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Dose escalation; Prostate cancer; Radiotherapy; Randomized trial; Subgroup analysis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; RADIATION FIELD; TREATMENT FAILURE;

AGED; CHI-SQUARE DISTRIBUTION; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77953961546     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.02.022     Document Type: Article

References (18)

1. Al-Mamgani A., van Putten W.L.J., Heemsbergen W.D., et al. Update of the Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 980-988
2. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
3. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239
4. For an important correction:. Zietman A.L. Correction: inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA 299 (2008) 898-900
5. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
6. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
7. Stephenson R.A. Prostate cancer trends in the era of prostate-specific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 29 (2002) 173-181
8. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
9. Bos L.J., Damen E.M.F., de Boer R.W., et al. Reduction of rectal dose by integration of the boost in the large-field treatment plan for prostate irradiation. Int J Radiat Oncol Biol Phys 52 (2002) 254-265
10. Chism D.B., Hanlon A.L., Horwitz E.M., Feigenberg S.J., and Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 380-385
11. Zelefsky M.J., Yamada Y., Fuks Z., et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 1028-1033
12. Cheung R., Tucker S.L., Lee A.K., et al. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external bean radiotherapy. Int J Radiat Oncol Biol Phys 61 (2005) 993-1002
13. Roach M I.I.I., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer. Recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
14. Kuban D.A., Thames H.D., Levy L.B., et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57 (2003) 915-928
15. De Meerleer G.O., Fonteyne V.H., Vakaet L., et al. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol 82 (2007) 16-166
16. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-108
17. Zapatero A., Valcarcel F., Calvo F.A., et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 23 (2005) 6561-6568
18. Pinover M.V., Hanlon A.L., Horwitz E.M., and Hanks G.E. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/ml prostate cancer. Int J Radiat Oncol Biol Phys 47 (2000) 649-654